Close

Idenix (IDIX) Shares at Intraday Low; INFORM-SVR Data Has Negative Implications & Abbott (ABT) Positive Hep C Studies

April 4, 2012 12:57 PM EDT
Get Alerts IDIX Hot Sheet
Price: $24.50 --0%

Rating Summary:
    1 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Join SI Premium – FREE
Shares of Idenix (Nasdaq: IDIX) are trading close to intraday lows, currently at $8.99, down $1.26 (-12.31%).

Brean Murray analyst, Brian Skorney, made comments after Roche's (OTC: RHHBY) reported unacceptable relapse rates for patients taking mericitabine+danoprevir+ritonavir+ribavirin for 12 wks.

Skorney, said, "We believe Idenix (Sell-rated) will need to explore regimens with durations of greater than 12 weeks to be effective. Given that the company has yet to initiate preclinical tox work in excess of 12 weeks, we believe this could significantly delay clinical development and makes IDX184 substantially less attractive as a potential backbone therapy."

Separately, shares of Idenix may be selling off after a report out from Abbott Labs (NYSE: ABT) this morning regarding results from clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV).

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 95% and 93% of treatment-naive genotype 1 (GT1) patients.

In a separate study, known as "Pilot," 91% of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Trader Talk

Related Entities

Brean Murray Carret & Co.